Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy.
Laura TestaMax Senna ManoRoberto Jun AraiRenata Colombo BonadioSergio Vicente SerranoMarina M Costa ZorzettoSusanne Crocamo Ventilari da CostaOren SmaletzRui Gilberto FerreiraPaulo Marcelo Gehm HoffPublished in: Clinics (Sao Paulo, Brazil) (2021)
The humanized anti-Lewis Y monoclonal antibody, hu3S193, exhibited insufficient activity in this cohort. However, the possibility of activity in a more strictly selected subgroup of patients with higher levels of Lewis Y tumoral expression cannot be overlooked.